Clinical trials

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Orphan drugs #Pharmokinetics #Preclinical #RNA #Screening #Target validation #Toxicology

BioPharma and CROs Collaborating In Early Drug Discovery

BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop BioPharma and CROs are riding the latest wave - discovery research - together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Gene editing #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Organic chemistry #Precision medicine #Preclinical #Regulatory #RNA #Screening #System biology #Target validation #Translational #Translational chemistry

Misconduct in the biomedical sciences part 2: detection and prevention

Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge. The key distinction that separates science from other… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Antimicrobials #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Molecular medicine #Oncology #PCR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections By Dr Vu Truong, Dr Nadine Weich, Dr Andreas Loos and Dr Eric Patzer The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and expensive due… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order for their… Read More

#Archive

#Academic #Animal models #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Oncology #Pathology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Experimental therapeutics for celiac disease and refractory celiac disease.

Experimental therapeutics for celiac disease and refractory celiac disease. By Dr Francisco Leon and Beth Llewellyn Celiac disease is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. In celiac patients, gluten causes a systemic autoimmune disease which starts in the small intestine but spreads to other organs… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Metabolomics #Molecular medicine #Oncology #PCR #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Precise genome editing: the key to a CRISPR drug discovery pipeline?

Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Precision medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Misconduct in the biomedical sciences part 1: issues and causes

Misconduct in the biomedical sciences part 1: issues and causes By Dr Gerald H. Lushington and Rathnam Chaguturu Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results - an… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Enabling technologies #Gene therapy #Genomics #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Precision medicine #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Therapeutic Drug Repurposing, Repositioning and Rescue Part II

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable. The activity and productivity of DRPx… Read More

#Archive

#Academic #Analytical chemistry #Animal models #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Toxicology

The Chinese Biologics Drug Market: Demand and Execution

By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Immunotherapy: The coming of age of cancer immunotherapy as a treatment paradigm

Immunotherapy: The coming of age of cancer immunotherapy as a treatment paradigm By Dr Jean Pierre Wery As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are still very… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Enabling technologies #Regulatory #RNA

TMFs become key differentiator for CROs as stakeholders demand better collaboration and access

TMFs become key differentiator for CROs as stakeholders demand better collaboration and access By Rik Van Mol R&D outsourcing continues to rise sharply to meet the demands of life sciences organisations’ growing pipelines, but CROs have to keep evolving or more nimble competitors will take their place. Regulatory pressures are… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Restucturing Proteomics: The rise of next-generation affinity reagents

Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Opportunities For Phenotypic Screening In Drug Discovery

Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference By Dr David Suhy A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are now starting to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Lead discovery #Orphan drugs #Regulatory #RNA

Principles for Winning Digital Health Strategies

Principles for Winning Digital Health Strategies By Dr Thilo Kaltenbach In a recent study on digital health in the pharmaceutical industry, management consultancy Arthur D. Little provided an industry snapshot of pharmaceutical companies’ goals for 2020 and their progress so far. The study indicated that by 2020, the business model… Read More

#Archive